Tech Company Financing Transactions
Amphivena Therapeutics Funding Round
Amphivena Therapeutics, operating out of San Francisco, secured $62 million from NanoDimension, Qiming Ventures and AJU IB Investment.
Transaction Overview
Company Name
Announced On
9/25/2019
Transaction Type
Venture Equity
Amount
$62,000,000
Round
Series C
Investors
NanoDimension (Lead Investor)
Qiming Ventures (Lead Investor)
Proceeds Purpose
This funding enables us to study the therapeutic impact of selective MDSC removal in both hematologic and solid cancers and to advance AMV564 and our novel T cell engagement portfolio to the forefront of immuno-oncology.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2 Tower Pl. 1000
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
Our mission is to eradicate blood cancers with a breakthrough therapy that harnesses the patient's own immune system to destroy tumor cells and precursors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeanmarie Guenot
Chief Scientific Officer
Victoria Smith
VP - Bus. Development
Patrick Chun
VP - Operations
Amy Penticoff
Browse more venture capital transactions:
Prev: 9/25/2019: Shopmonkey venture capital transaction
Next: 9/25/2019: Cowbell Cyber venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document tech company VC transactions. VC transactions reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs